Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth by Curtis, Donna J. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Supported Publications 
University of Massachusetts Center for Clinical 
and Translational Science 
2015-03-18 
Characterization of functional antibody and memory B-cell 
responses to pH1N1 monovalent vaccine in HIV-infected children 
and youth 
Donna J. Curtis 
University of Colorado School of Medicine 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/umccts_pubs 
 Part of the Immune System Diseases Commons, Influenza Virus Vaccines Commons, Pediatrics 
Commons, Therapeutics Commons, Translational Medical Research Commons, and the Virus Diseases 
Commons 
Repository Citation 
Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, 
Cunningham CK, Bloom A, Weinberg A. (2015). Characterization of functional antibody and memory B-cell 
responses to pH1N1 monovalent vaccine in HIV-infected children and youth. UMass Center for Clinical 
and Translational Science Supported Publications. https://doi.org/10.1371/journal.pone.0118567. 
Retrieved from https://escholarship.umassmed.edu/umccts_pubs/52 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Supported Publications by an authorized administrator of eScholarship@UMMS. 
For more information, please contact Lisa.Palmer@umassmed.edu. 
RESEARCH ARTICLE
Characterization of Functional Antibody and
Memory B-Cell Responses to pH1N1
Monovalent Vaccine in HIV-Infected Children
and Youth
Donna J. Curtis1*, Petronella Muresan2, Sharon Nachman3, Terence Fenton2, Kelly
M. Richardson1, Teresa Dominguez1, Patricia M. Flynn4, Stephen A. Spector5, Coleen
K. Cunningham6, Anthony Bloom7, AdrianaWeinberg1,8*
1 Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, United States
of America, 2 Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts,
United States of America, 3 SUNY Stony Brook, Stony Brook, New York, United States of America,
4 St. Jude's Children's Hospital, Memphis, Tennessee, United States of America, 5 University of California
San Diego, La Jolla, California, and Rady Children’s Hospital, San Diego, California, United States of
America, 6 Duke University Medical Center, Durham, North Carolina, United States of America, 7 Frontier
Science and Technology Research Foundation, Amherst, New York, United States of America,
8 Departments of Medicine and Pathology, University of Colorado School of Medicine, Aurora, Colorado,
United States of America
* donna.curtis@ucdenver.edu (DJC); adriana.weinberg@ucdenver.edu (AW)
Abstract
Objectives
We investigated immune determinants of antibody responses and B-cell memory to pH1N1
vaccine in HIV-infected children.
Methods
Ninety subjects 4 to<25 years of age received two double doses of pH1N1 vaccine. Serum
and cells were frozen at baseline, after each vaccination, and at 28 weeks post-immuniza-
tion. Hemagglutination inhibition (HAI) titers, avidity indices (AI), B-cell subsets, and pH1N1
IgG and IgA antigen secreting cells (ASC) were measured at baseline and after each vacci-
nation. Neutralizing antibodies and pH1N1-specific Th1, Th2 and Tfh cytokines were mea-
sured at baseline and post-dose 1.
Results
At entry, 26 (29%) subjects had pH1N1 protective HAI titers (1:40). pH1N1-specific HAI,
neutralizing titers, AI, IgG ASC, IL-2 and IL-4 increased in response to vaccination
(p<0.05), but IgA ASC, IL-5, IL-13, IL-21, IFNγ and B-cell subsets did not change. Subjects
with baseline HAI1:40 had significantly greater increases in IgG ASC and AI after immuni-
zation compared with those with HAI<1:40. Neutralizing titers and AI after vaccination in-
creased with older age. High pH1N1 HAI responses were associated with increased IgG
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ASC, IFNγ, IL-2, microneutralizion titers, and AI. Microneutralization titers after vaccination
increased with high IgG ASC and IL-2 responses. IgG ASC also increased with high IFNγ
responses. CD4% and viral load did not predict the immune responses post-vaccination,
but the B-cell distribution did. Notably, vaccine immunogenicity increased with high CD19
+CD21+CD27+% resting memory, high CD19+CD10+CD27+% immature activated, low
CD19+CD21-CD27-CD20-% tissue-like, low CD19+CD21-CD27-CD20-% transitional and
low CD19+CD38+HLADR+% activated B-cell subsets.
Conclusions
HIV-infected children on HAARTmount a broad B-cell memory response to pH1N1 vaccine,
which was higher for subjects with baseline HAI1:40 and increased with age, presumably
due to prior exposure to pH1N1 or to other influenza vaccination/infection. The response to





Influenza viruses cause yearly epidemics and occasional pandemics that are associated with sig-
nificant morbidity and mortality. Immunocompromised individuals, including HIV-infected
children and adults, have higher rates of influenza morbidity and mortality, proportionate to
their degree of immunodeficiency [1–3]. Studies of immune correlates of protection against in-
fluenza infection have identified the role of neutralizing antibodies in preventing infection of
the host cells and of cell-mediated immunity (CMI) in clearing already-infected cells. Further-
more, hemagglutination inhibition (HAI) antibody titers1:40 were associated with a 50% de-
crease in the incidence of influenza disease. This observation led HAI titers 1:40 to become
the current benchmark for evaluating the immunogenicity of influenza vaccines.
HIV-infected individuals generally have poor antibody and CMI responses to influenza vac-
cines, particularly in the context of advanced HIV disease and in the absence of highly active
antiretroviral therapy (HAART) [4–6]. Individuals who do not have progressive HIV-1 disease
and/or are receiving HAART have improved responses to vaccines [7–9], but do not tend to
reach the same HAI titers or CMI as healthy age-matched controls. The mechanisms underly-
ing the poor antibody responses to influenza vaccines in HIV-infected individuals are only par-
tially understood. Antibody responses to influenza vaccines are T-cell dependent and,
therefore, are affected by the functionality of T helper 1 (Th1) cells, which play an important
role in antibody responses to viral pathogens [10], and of T follicular helper (Tfh) cells, which
have recently been identified as the key stimulators of T-dependent antibody production [11].
Both Th1 and Tfh functions are compromised in HIV-infected individuals, contributing to the
low immunogenicity of vaccines including influenza [12–14]. In addition, multiple B-cell ab-
normalities have been identified in HIV-infected individuals [15], which may also play a role
in the poor antibody responses to vaccines. Although HIV does not replicate in B cells, it inter-
feres with B-cell function through multiple interactions: gp120 and cellular DC-SIGN; CD40L
incorporated into the virion membrane and cellular CD40; and complement fixing HIV
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antigen-antibody complexes with cellular CD21 [16–22]. In addition, HIV Nef protein can be
delivered to the B cells through immunologic synapses with CD4+ T cells and/or macrophages
and impede the NFkB pathway, while also activating the SOCS pathway [19]. Additional indi-
rect effects of HIV on B cells result from inflammation and lymphopenia. These ultimately
translate into impaired immunoglobulin class switch recombination, loss of resting memory
B cells (CD21+CD27+), abnormally high proportions of immature (CD10+) and activated
(CD21-CD27+, CD95+ and/or CD38+) B cells, and increased B-cell turn-over and apoptosis
[19,23–25]. All these factors may contribute to the decreased antibody responses to infections
and vaccines [18,26–29]. Furthermore, only some of the B-cell abnormalities are averted by
lack of disease progression or reversed with HAART [30,31]. To best target the efforts to im-
prove the immunogenicity of vaccines in HIV-infected individuals, it is critically important to
understand the relative contributions of each of these factors to the B cell responses
to vaccines.
The goal of this study was to assess the effect of abnormal B-cell maturation and activation
and/or dysfunctional T-cell help on the magnitude, quality and memory of the humoral im-
mune response to a pH1N1 vaccine. The primary outcome measures of this analysis were HAI
and microneutralization titers, antibody avidity, and B cell memory measured by ELISPOT.
The subjects were HIV-infected children and youth who participated in the International Ma-
ternal Pediatric and Adolescent Clinical Trials (IMPAACT) Network’s P1088, a study of the
safety and immunogenicity of pH1N1 monovalent influenza immunization [32]. P1088 HAI
results and analysis of the regulatory B and T cells have been previously reported by Flynn et al
[32] and Weinberg et al [33] respectively. Here, we provide a detailed analysis of neutralizing
antibody responses, antibody avidity and IgG and IgA B-cell memory as a function of Th1,
Tfh, circulating B-cell subsets, age and HIV disease characteristics.
Subjects and Methods
Study Design
This was a substudy of P1088 (NCT00992836), approved through an amendment to the parent
P1088 study entitled NewWorks Concept Sheet 114 (NWCS 114). In the parent study, 155
perinatally HIV-infected children and youth, aged4 to<25 years, were recruited from 37 dif-
ferent IMPAACT sites in the US and Puerto Rico between October 14 and November 12, 2009.
Subjects on stable antiretroviral therapy for90 days prior to entry received two 30 μg doses of
2009 Novartis Influenza A (pH1N1) monovalent vaccine (Fluvirin), separated by 21–28 days.
Seasonal influenza vaccine administration was restricted to2 weeks before enrollment and to
2 weeks after the 2nd pH1N1 dose. A full description of the parent study can be found in
Flynn et al, JID 206:421–430.[32]
The enrollment in the parent study was stratified into 3 age groups (Fig. 1), chosen based on
immunologic and physiologic differences. Children<9 years of age generally mount insuffi-
cient antibody responses to influenza vaccines administered for the first time. This is generally
accepted and acknowledged by the CDC recommendation to administer 2 doses of vaccine
under these circumstances. The age of 18 years is generally considered the transition from ado-
lescence to adulthood, which may also be associated with immunologic changes. Therefore the
accrual was stratified into 3 age groups: 4 to<9, 9 to<18 and 18 to<25 years of age. The cur-
rent substudy followed the same stratification for subject inclusion and analysis. 90 participants
with available samples were selected from the 155 P1088 study participants, such that both
complete responders (defined by an HAI titer1:40 and 4-fold increase post-dose 1 com-
pared to baseline) and non-responders were well represented, with the goal of having up to half
of the subjects in each group be non-responders. This required including all nonresponders
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with available samples and randomly selecting responders to complete the N = 30 for each
age group.
Vaccines were given at week 0 (baseline) and at 21–28 days after the first vaccine. Blood for
immunologic assays was collected at week 0, 21–28 days post-dose 1 (coinciding with the ad-
ministration of the 2nd vaccine), 10–14 days post-dose 2, and at 28 weeks post-dose 1. The tim-
ing of the blood draws was designed to obtain a pre-vaccination sample, a sample at the peak
of the immune response to vaccine dose 1 (and to allow at least 3–4 weeks between vaccina-
tions), a sample at the peak of the immune response to dose 2, and a sample at the end of the
influenza season to measure persistence of the antibodies. Throughout the manuscript, these
timepoints are referred to as: baseline or week 0, post-dose 1 or week 3, post-dose 2 or week 5,
and 28 weeks.
The CONSORT Checklist, the original P1088 protocol for this trial, and the P1088 Protocol
and P1088 NWCS 114 Amendment for this current study are available as supporting informa-
tion (see S1 CONSORT Checklist, S1 Protocol, S2 Protocol). The study was approved by local
IRBs. Written consent and assent were obtained from participants and/or legal guardians as
appropriate. Further information on the participating sites and their Institutional Review
Fig 1. Flow Chart after Enrollment. Abbreviations: ARVs, antiretrovirals; HAI, hemagglutinin inhibition;
PBMCs, Peripheral blood mononuclear cells. *Reasons for exclusion from the final analysis included:
insufficient sample to perform assay, invalid results of assay
doi:10.1371/journal.pone.0118567.g001
Immune Responses to pH1N1 Vaccine in HIV-Infected Children
PLOS ONE | DOI:10.1371/journal.pone.0118567 March 18, 2015 4 / 21
Boards can be found in the Acknowledgments and (see S1 List for a list of participating
IMPAACT sites). This substudy was approved by the Colorado Multiple Institutional Review
Board (COMIRB), and all assays of the substudy were performed at the University of Colorado
School of Medicine.
Neutralizing antibodies
An ELISA-based microneutralization was performed as previously described [34,35] on sera
collected at baseline and post-dose 1. Briefly, serial 2-fold dilutions of sera starting at 1:10 in
phosphate-buffered solution (PBS) were added in duplicate to 100 TCID50 of pH1N1 influenza
virus and 1.5 x 104 MDCK cells in 96-well microtiter plates. Cell control and virus control wells
were included on each plate. After 18–22 hours of incubation in a humidified atmosphere at
37°C and 5% CO2, the cell monolayer was fixed and the ELISA was performed using 100μL
anti-influenza A NP mouse antibodies (Millipore, cat. # MAB8257 &MAB8258) followed by
goat anti-mouse IgG conjugated to horseradish peroxidase (HRP) secondary antibodies (KPL,
cat. # 074–1802). Bound antibodies were revealed with 3,3’,5,5’-Tetramethylbenzidine (TMB)
substrate. The optical density (OD) was measured with a Multiscan FC ELISA reader (Thermo
Fisher) using a 450 nm filter. The neutralizing titer was calculated using the following equation:
[median OD of virus control wells + median OD of cell control wells]/2. Samples with discor-
dance larger than 1 dilution between replicates were repeated.
Antibody avidity
The assay was adapted from a previously described ELISA-based method with urea denatur-
ation [36]. 96-well Immulon 2 HB microplates (Thermo Scientific) were coated for 20–24
hours at 4°C[36] with monovalent 2009 pH1N1 inactivated influenza vaccine (Sanofi-Pasteur)
at a pre-optimized amount of 15ng/well. After blocking (PBS with 0.1% Tween and 0.2% FBS)
for 120 min, 100μL of serum diluted at 1:1000 in PBS were added to duplicate wells. Plates were
incubated with serum for 1 hour at 37°C after which 100μL of 8M urea solution in PBS were
added to urea-treated wells and 100μL of PBS to control wells. After a 15 minute-incubation at
room temperature, plates were washed and bound antibodies were revealed with HRP-conju-
gated goat anti-human IgG antibodies (Sigma-Aldrich; A0170) and TMB substrate as above. Ti-
ters were calculated by interpolating the average OD of replicate test wells on a standard curve
created with serial dilutions of a unique control sample. Results were considered valid if the OD
of the test sample was within the dynamic range of the assay. For OD’s outside the dynamic
range, the test was repeated at a higher or lower dilution. The avidity index (AI) was calculated
by dividing the ELISA units of the urea-treated sample by those of the urea-untreated sample.
IgG/IgA FluoroSpot
Cryopreserved PBMCs were used for the detection of IgG/IgA antibody secreting cells (ASC).
Cells were thawed, counted and then stimulated in RBMI 1640 (Gibco) with 10% fetal bovine
serum (Gemini Bio-Products), 0.4% penicillin and streptomycin, 1% Hepes buffer (Corning
Cellgrow), 1μg/mL Staphylococcus aureus Cowan (Sigma-Aldrich), 6μg/mL CpG (Operon
Technologies), and 1μg/mL pokeweed mitogen (Sigma-Aldrich) for 96 hours at 37° C, 5%
CO2. PBMCs with viability55% were used at 50,000 cells/well in duplicate wells of the
FluoroSpot IgG/IgA kits (Mabtech Inc.). Assays were performed as per manufacturer’s instruc-
tions using pH1N1 antigen, HAI titer 1:1024, to coat the plates and an ImmunoSpot II (Cell
Technologies Ltd.) instrument to count the ASC. Results are expressed as ASC/106 stimulated
PBMCs.
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B-cell phenotypic characterization
B-cell subsets were measured in freshly thawed cryopreserved PBMCs. After washing and
counting viable cells, PBMCs were surface-stained with the following conjugated mAbs: anti-
CD19-PE-Cy5, anti-CD21-PE, anti-CD20-PE-Cy7, anti-CD27-APC, anti-IgM-FITC, anti-
CD38-FITC, anti-HLA-DR-PE-Cy7 (BD Bioscience); anti-CD10-APC-Cy7, anti-BAFFr-APC-
Cy7 (Biolegend); anti-TACI-PE, anti-CxCr5-APC (R & D Systems) and analyzed with Guava
easyCyte 8HT (Millipore) and FlowJo (Treestar). Subsets were expressed as percentages of the
parent CD19+ B-cell population.
Inducible cytokines
IFNγ, IL-2, IL-4, IL-5, and IL-13 were measured by multiplex bead array and IL-21 by ELISA
using supernatants of PBMC cultures stimulated for 48 hours with pH1N1 and mock control
as previously described [33]. Culture supernatants were stored at -80°C until assayed in batch.
The bead array assays used the MILLIPLEX MAP High Sensitivity Human Cytokine Magnetic
Bead Panel kit (Millipore; HSCYTMAG-60SK) on the Bio-Rad Bio-Plex 200 instrument per
manufacturer’s instructions. The lower level of detection (LLOD) was 0.08–1.01pg/mL and the
dynamic range 13–2,000pg/mL. Data were analyzed using Bio-Plex manager 5.0 software
(manufacturer Bio Rad) and concentrations were interpolated on the manufacturer’s standard
curve using PRISM software (Graphpad). IL-21 concentrations were measured with the
Human IL-21 ELISA Ready-SET-Go! (e-Bioscience; 88–7216) kit per manufacturer’s protocol.
The LLOD was 31 pg/mL and the dynamic range 31–4,000pg/mL. OD’s were measured as
above. Test supernatant concentrations were calculated using PRISM software.
Statistical Analyses
The baseline HIV disease characteristics were summarized and compared among the three age
groups using a Fisher’s Exact test for gender, race (black vs. other), ethnicity (Latino vs. other)
and an ANOVA test for CD4%, CD8% and log10 RNA count. The rates of HAI and microneu-
tralization titers1:40 at baseline were compared among the three age groups using a Fisher’s
Exact test. HAI and microneutralization titers<1:10 were considered undetectable and were
assigned a value of 1:5. Microneutralization titers post vaccination and pre-post changes in
these titers were compared across the three age groups using a Kruskal-Wallis test. Changes in
antibody avidity, B-cell memory responses, phenotypic characterization of B-cell subsets and
inducible cytokine levels between different time points were assessed using Wilcoxon Matched
Pairs Signed-Rank tests. The groups of participants with baseline HAI titers40 vs.<40 were
compared with respect to these measures post vaccination using a Wilcoxon Rank-Sum test.
The final flow cytometry analyses were restricted to samples with40 events in the anchor
gate. However, a sensitivity analysis showed that the inclusion of samples with<40 events in
the anchor gate would not have changed the results. Spearman correlation analyses were per-
formed to assess the strength of associations on data at specific time points and test their statis-
tical significance. All analyses were performed using SAS Version 9.2 (SAS Institute INC, Cary,
NC) and the graphs were produced using the R software.
Results
Baseline characteristics of the study population and the HAI responses
to pH1N1 vaccine
The characteristics of the 90 children and youth who participated in this substudy are summa-
rized in Table 1. The CD4+ T cells had mean ±S.D. of 33 ±9.3% for the entire cohort and
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differed significantly across the age groups (the older age group had lower mean than the youn-
ger groups, p<0.001). HIV plasma RNA had mean±S.D. of 2.1±0.9 log10 copies/mL for the en-
tire cohort and was higher in the older compared with the younger groups (p<0.001). At
baseline, 26 participants (29%) were seroprotected against pH1N1 (as defined by HAI titers
1:40). Seroprotection at baseline was less common in the younger group (age 4 to<9, 13%)
compared with the older groups (age 9 to<18, 30%, and age 18 to<25, 43%). After the 1st
dose of vaccine, the proportions of seroprotected subjects and of complete responders (defined
by HAI1:40 and4-fold increase in antibody titers compared to baseline) were 62/90 (69%)
and 56/90 (62%), respectively, and did not significantly differ across age groups (p = 0.41 and
0.80, respectively). Demographic and HIV disease characteristics of the 90 substudy partici-
pants and of the parent study participants not included in the substudy were similar
(S1 Table).
Viral neutralization function of the antibody response to pH1N1 vaccine
Microneutralization assays were performed on all subjects at baseline and post-dose 1
(Table 2). There was a significant increase in the median microneutralization titers in response
to vaccination from 1:5 to 1:20 (p<0.0001). Although median titers increased in all age groups
from baseline to post-dose 1, the proportion of subjects seroprotected (defined by a titer
Table 1. Characteristics of the Study Population.
Variable All 4-<9 years of age 9-<18 years of age 18-<25 years of age P value among groupsc
Total Number of Subjects 90 30 30 30
Gender Female 47 (52%) 16 (53%) 14 (47%) 17 (57%) 0.81*
Race and Ethnicity
Black 53 (59%) 16 (53%) 18 (60%) 19 (63%) 0.82*
Latino 33 (37%) 15 (50%) 11 (37%) 7 (23%) 0.10*
Age (yrs)
Mean 13 6 14 20
Standard Deviation 5.9 1.5 2 1.7
CD4 Percent
Mean 33 38 33 28 <0.001**
Standard Deviation 9.3 6.4 7.6 10.7
CD8 Percent
Mean 37 28 38 46 <0.001**
Standard Deviation 13.6 6.2 13.9 13.2
Log 10 RNA Count
Meana 2.1 1.8 1.99 2.5 0.002**
Standard Deviation 0.9 0.5 0.7 1.1
Baseline pH1N1 HAI 1:40 26 (29%) 4 (13%) 9 (30%) 13 (43%) 0.04*
Post-dose 1 pH1N1 HAI 1:40 62 (69%) 18 (60%) 21 (70%) 23 (77%) 0.41*
Post-dose 1 complete responseb 56 (62%) 17 (57%) 20 (67%) 19 (63%) 0.80*
a. The lower limit of detection varied among subjects depending on the assay used at the speciﬁc clinical research site; RNA values below the limit of
detection were replaced with the lower limit of the assay (eg, 18 cp/mL was replaced with 50 cp/mL for an assay with the limit of detection of 50 cp/mL).
b. Complete response is deﬁned as persons achieving both seroresponse and seroprotection.
c. P values among age groups were calculated by:
* Fisher’s Exact Test
**Analysis of Variance
doi:10.1371/journal.pone.0118567.t001
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1:40) after vaccination increased with the ages of the groups (23.3%, 50.0%, and 70.0% for
younger, middle and older groups, respectively; p = 0.001). Excluding those with baseline
microneutralization titers1:40, the proportions of seroprotected post-vaccination were
17.9%, 38.1%, and 60.9% in the younger, middle and older groups, respectively (p = 0.008).
Furthermore, the proportions of subjects who had a4-fold increase in microneutralization
titer in response to vaccine also increased with age (36.7%, 44.4% and 70.0%, respectively; p =
0.03). The difference across age groups in the proportion of participants with4-fold-rises was
significant among subjects with microneutralization titers<1:40 at baseline (p = 0.03), but not
in subjects with baseline titers1:40 (p = 0.3), where the relatively small sample size provided
limited precision and power. The proportions of complete responders increased with the ages
of the groups regardless of the baseline microneutralization titers.
Avidity of antibody responses to pH1N1 vaccine
Antibody avidity was measured at baseline, after each dose of vaccine and at 28 weeks. The AI
significantly increased (p = 0.04) only after the 2nd dose of vaccine, from a median of 0.11 at
baseline to 0.17 post-dose 2 (Fig. 2A) and remained marginally higher than baseline at 0.14 at
week 28 (p = 0.07; Fig. 2A). It is interesting to note that only participants with baseline HAI ti-
ters1:40 had significant AI increases after vaccination (median = 0.10, 0.18, 0.21 and 0.15 for
baseline, post-dose 1, post-dose 2 and week 28 respectively, p of<0.0001,<0.0001 and 0.003
for change from baseline; Fig. 2A), whereas in participants with baseline HAI<1:40 the AI did
not change significantly (median = 0.11, 0.13, 0.13 and 0.13 for baseline, post-dose 1, post-dose
Table 2. Neutralizing Antibody Responses after the 1st Dose of pH1N1 Vaccine.
Age Groups
All (N = 89) 4 to <9 (N =
30)
9 to <18 (N =
29)




Baseline titer, Median (IQRa) 5 (5,5) b 5 (5,5) 5 (5,30) 5 (5,20) 0.09*
Post vaccine titer, Median (IQR) 20 (5,80) 10 (5,20) 30 (8,120) 60 (20,160) 0.006*
Median fold-change in titer (IQR) post vaccine 4 (1,8) 2 (1,4) 2 (1,8) 6 (2,16) 0.02*
% Seroprotection (microneutralization titer 1:40)
Baseline, all subjects 18.2% 6.7% 25% 23.3% 0.12**
Post vaccine, all subjects 47.7% 23.3% 50% 70% 0.001**




17.9% (5/28) 38.1% (8/21) 60.9% (14/23) 0.008**
% Seroresponse (4-fold change in titer vs. baseline)
All subjects 50.6% 36.7% 44.4% 70% 0.03**
Subjects with baseline microneutralization <1:40 48.6% (35/
72)
32.1% (9/28) 47.6% (10/21) 69.6% (16/23) 0.03**
Subjects with baseline microneutralization 1:40 60% (9/15) 100% (2/2) 33.3% (2/6) 71.4% (5/7) 0.3**
% Complete response (titer 1:40 post-vaccine and 4-fold change in titer vs. baseline)
All subjects 37.1% 23.3% 27.6% 60% 0.01**
Subjects with baseline microneutralization <1:40 33.3% 17.9% 28.6% 56.5% 0.01**
a. IQR = Interquartile Range
b. Numbers represent the reciprocal of pH1N1 microneutralization titers.
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Fig 2. Changes in Antibody Avidity after pH1N1 Vaccination by Age Group and Baseline HAI.Data
were derived from HIV-infected children and youth who received 2 doses of pH1N1monovalent vaccine (30
μg/dose) approximately 3 weeks apart. Data represent medians and Inter Quartile Range (IQR) of the avidity
index (AI). The number of subjects per group at each time point is listed on the graph.A presents the AI
responses for all subjects and also for the subjects divided by baseline pH1N1 HAI immune serostatus (HAI
titer<1:40 versus1:40). Overall, AI significantly increased post-dose 2 (p = 0.04) and remained slightly
higher at 7 mo (p = 0.07). Only subjects seroprotected at baseline had significant AI increases after
vaccination (p<0.0001,<0.0001 and 0.003 post-dose 1, post-dose 2 and 7 months post-dose 1,
respectively). Baseline seropositive participants with HAI titers 1:40 had a significantly higher AI response
to vaccination compared with participants with baseline HAI titers<1:40 (p = 0.02 at both post-dose 1 and
post-dose 2). B shows AI responses in each age group. In the 4 to<9-year old group, there were no
significant differences in AI between baseline and any subsequent time point. In the 9 to<18-year old group,
there were significant AI increases at post-dose 2 and at 7 months (p = 0.04 and 0.048 respectively). In the 18
to<25-years old group, there were significant differences from baseline at all time points (p = 0.02, 0.04 and
0.002, respectively).
doi:10.1371/journal.pone.0118567.g002
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2 and week 28 respectively, p0.87 for change from baseline). Baseline seropositive partici-
pants with HAI titers 1:40 had a significantly higher AI response to vaccination compared
with participants with baseline HAI titers<1:40 (p = 0.02 at both post-dose 1 and post-dose 2;
Fig. 2A). AI did not increase after vaccination in the younger age group (median = 0.12, 0.14,
0.13 and 0.15 for baseline, post-dose 1, post-dose 2 and week 28, respectively, p of 0.41, 0.62
and 0.23 for change from baseline; Fig. 2B); AI significantly increased after the 2nd dose of vac-
cine and remained increased at week 28 in the middle age group (median = 0.09, 0.14, 0.19 and
0.11 for baseline, post-dose 1, post-dose 2 and week 28 respectively, p of 0.2, 0.04 and 0.048 for
change from baseline; Fig. 2B); and AI significantly increased at all visits after the 1st dose of
vaccine in the older age group (median = 0.11, 0.14, 0.17 and 0.15 for baseline, post-dose 1,
post-dose 2 and week 28 respectively, p of 0.02, 0.04 and 0.002 for change from baseline;
Fig. 2B).
B-cell memory responses to pH1N1 vaccine
B-cell memory was assessed by the number of pH1N1-specific IgG and IgA antibody secreting
cells (ASC)/106 PBMCs. At baseline, the median IgA and IgG ASC were 0 and 6 respectively.
After immunization, there was no change in IgA ASC (not depicted), but the IgG ASC signifi-
cantly increased after the 1st dose to 13 (p = 0.048) and plateaued thereafter (Fig. 3A). Although
the analysis of IgG ASC change from baseline post-dose 1 and post-dose 2 did not show signifi-
cant differences when the groups were stratified by baseline HAI positivity, baseline seroposi-
tive participants (HAI titers 1:40) had significantly higher IgG ASC post-dose 2 compared
with baseline seronegative participants (HAI titers<1:40; p = 0.03; Fig. 3A). There were no sig-
nificant changes in IgG ASC after vaccination when subjects were stratified by age (Fig. 3B).
pH1N1-specific Th1, Th2 and Tfh responses to pH1N1 vaccine
Th1 cytokines IFNγ and IL-2, Th2 cytokines IL-4, IL-5 and IL-13, and the Tfh cytokine IL-21
were measured at baseline and post-dose 1 in pH1N1-stimulated PBMCs culture supernatants.
pH1N1-induced IL-2 and IL-4 were the only cytokines with significant increases from baseline
to post-dose 1 (p = 0.01 and p = 0.004 respectively; Table 3).
Correlations among the pH1N1-specific B- and T-cell immune
responses to pH1N1 vaccine
To determine the extent of the coordination between the different components of the immune
response to pH1N1 vaccine, including magnitude and functionality of the antibodies and gen-
eration of B cell memory and of T-cell help, we performed correlation analyses before and after
vaccination between HAI, microneutralization, avidity, IgG ASC and cytokine production
(Table 4). Correlation results represent the correlation of the laboratory results at that time
point for each of the variables. The data showed strong positive correlations between HAI and
microneutralization titers at all time-points (p<0.0001). HAI titers were also significantly cor-
related with pH1N1-specific IL-2 and IFNg production at all time-points analyzed (p<0.03);
with IgG B cell memory responses only after vaccination; and with AI at post-dose 2, when sig-
nificant AI increases over baseline were detected for the first time. It is important to note that
before vaccination high HAI titers were associated with low AI, suggesting that not all HAI an-
tibodies at baseline were specific for pH1N1. The correlation analysis of microneutralization ti-
ters followed the same pattern as HAI. AI weakly correlated with IgG ASC at post-dose 1.
There were significant correlations of IgG ASC with pH1N1 IFNg production at all time-points
analyzed but not with IL-2. pH1N1-specific IL-21 production did not correlate with any of the
B cell responses to the vaccine (data not shown).
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Correlations of the response to pH1N1 vaccine with HIV disease
characteristics
Correlation analyses of CD4% and HIV plasma RNA with HAI titers, microneutralization ti-
ters, AI and IgG ASC responses to vaccination failed to show any significant associations
(S2 Table).
Fig 3. IgG ASCmeasured by ELISPOT (memory B-cells) at Baseline and after Vaccination. Data were
derived from HIV-infected youth and children who received 2 doses of pH1N1 inactivated monovalent
vaccine (30 μg/dose) approximately 3 weeks apart. Data represent medians and IQR of the IgG ASC/106
PBMCs at each timepoint. The number of subjects per group at each time point is listed on the graph. A
presents the IgG responses for all subjects and also for the subjects divided by baseline pH1N1 HAI immune
serostatus (HAI titer<1:40 versus1:40). After the first immunization there was a significant increase in IgG
ASC (p = 0.048). There were no statistical differences in IgG ASC within each HAI immune serostatus group
between baseline and the two vaccinations, but subjects with baseline HAI1:40 titers had significantly
higher IgG ASC after vaccination than those with titers<1:40 (p = 0.03). B depicts the median IgG ASC by
age group. There were no statistical differences in IgG ASC within each age group between baseline and the
two vaccinations.
doi:10.1371/journal.pone.0118567.g003
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Circulating B-cell subsets and their relationship with functional B-cell
responses to pH1N1 vaccine
The following B cell subsets were enumerated at baseline and after each vaccination: CD19
+CD21+CD27+ (resting memory); CD19+CD21+CD27-(naïve); CD19+CD21-CD27-CD20+
(tissue-like memory); CD19+CD21-CD27-CD20- (transitional); CD19+CD21-CD27+CD20-
(plasmablasts); CD19+CD10+ (immature); CD19+CD10+CD27+ (immature activated); CD19
+HLADR+CD38+ (activated); CD19+BAFFR+; CD19+TACI+; and CD19+CXCR5+. There
were no appreciable changes in B-cell subset distribution across visits. (S3 Table).
Table 3. Th1, Th2 and Tfh Responses to pH1N1 Vaccine.
Variablea Baseline Post-dose 1
Median (IQR) pg/mL N Median (IQR) pg/mL N P valued
IFNγb 19.69 (4.85,103.67) 71 26.53 (10.89,145.48) 72 0.12
IL-2b 56.72 (24.29,105.03) 72 63.38 (35.50,140.01) 72 0.01
IL-4b 28.70 (9.56,83.32) 67 52.66 (19.02,108.07) 70 0.004
IL-5b 1.00 (1.00,6.40) 56 1.00 (1.00,5.98) 62 0.78
IL-13b 15.81 (8.32,39.30) 72 15.83 (7.36,32.98) 70 0.44
IL-21c 75.69 (65.01,84.30) 68 70.80 (54.44,90.93) 70 0.81
a. Th1 (IFNγ, IL-2), Th2 (IL-4, IL-5, IL-13) and Tfh (IL-21) responses were measured in the supernatants of PBMC cultures stimulated with inﬂuenza
pH1N1 virus.
b. Measured by multiplex bead array (Luminex). Lower levels of detection were 0.08–1.01 pg/mL.
c. Measured by ELISA. Lower level of detection was 31 pg/mL.
d. P values calculated by Wilcoxon Matched Pairs Signed Ranks test.
doi:10.1371/journal.pone.0118567.t003
Table 4. Correlations of cellular and humoral B- and T-cell mediated immune responses to pH1N1.
Variable 1 Variable 2 Time point at which data from each variable was analyzed
Baseline Post-dose 1 Post-dose 2
ρ (p value) N ρ (p value) N ρ (p value) N
pH1N1 HAI Titers pH1N1 IgG ASC 0.15 (0.32) 46 0.45 (0.004) 40 0.34 (0.03) 40
pH1N1 IFNγ 0.37 (0.002) 71 0.26 (0.03) 72 NM
pH1N1 IL-2 0.31 (0.008) 72 0.40 (0.001) 72 NM
Microneutralization Titers 0.70 (<0.0001) 88 0.63 (<0.0001) 88 NM
Antibody Avidity -0.22 (0.04) 89 0.13 (0.21) 90 0.28 (0.01) 88
Microneutralization Titers pH1N1 IgG ASC 0.23 (0.14) 44 0.45 (0.005) 38 NM
pH1N1 IFNγ 0.30 (0.01) 68 0.13 (0.29) 69 NM
pH1N1 IL-2 0.30 (0.01) 69 0.39 (0.001) 69 NM
Antibody Avidity -0.32 (0.002) 87 0.14 (0.19) 88 NM
Antibody Avidity pH1N1 IgG ASC -0.03 (0.84) 44 0.29 (0.08) 38 0.09 (0.57) 38
pH1N1 IFNγ -0.13 (0.28) 69 0.08 (0.52) 71 NM
pH1N1 IL-2 -0.03 (0.81) 70 0.04 (0.75) 71 NM
B-cell memory (pH1N1 IgG ASC) pH1N1 IFNγ 0.39 (0.01) 43 0.53 (0.001) 38 NM
pH1N1 IL-2 -0.01 (0.93) 44 0.26 (0.12) 38 NM
NM = Not measured
doi:10.1371/journal.pone.0118567.t004
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Several B-cell subsets were significantly associated with the immunogenicity of the vaccine
in the HIV-infected study population (Table 5). High CD19+CD10+CD27+% (immature acti-
vated) cells and CD19+CD10+% (immature) cells showed a marginal correlation with high
pH1N1 HAI post-dose 2 (ρ0.26, p0.08). An increase in AI was significantly correlated with
low CD19+CD21-CD27-CD20+% (tissue-like memory) and CD19+CD21-CD27-CD20-%
(transitional) cells post-dose 2 (ρ-0.32, p = 0.03) and with high CD19+CD21+CD27+% (rest-
ing memory; ρ = 0.29, p = 0.05).
High CD19+CD10+CD27+% (immature activated) and CD19+CD21+CD27+% (resting
memory) were significantly correlated with increased IgG ASC post-dose 2 (ρ0.4, p0.01).
Low CD19+HLADR+CD38+% (activated), and CD19+CD21-CD27-CD20-% (transitional)
were also associated with high IgG ASC post-dose 2 (ρ = -0.36, p0.04), while low CD19
+CD21-CD27-CD20+% (tissue-like memory) was associated with high IgG ASC post-dose 1
(ρ = -0.41, p = 0.01). There were marginal correlations between 1) high IgG ASC post-dose 1
and high CD19+CD21+CD27+% (resting memory) and CD19+CD21-CD27+CD20- (plasma-
blasts; ρ0.28, p0.08); and 2) low IgG ASC post-dose 2 and high CD19+CD21+CD27-%
(naïve; ρ = -0.28, p = 0.09). In addition, at baseline, high IgG ASC was associated with high
CD19+BAFFR+% (rho = 0.32; p = 0.046) (data not shown).
It is interesting to note that for some phenotypes, such as CD19+CD21+CD27+% resting
memory (Fig. 4A), CD19+HLADR+CD38+% activated (Fig. 4B) and CD19+CD21-CD27-
CD20-% transitional B cells (Fig. 4C), the magnitude of the coefficient of correlation with IgG
ASC progressively increased from baseline to post-dose 1 and 2 suggesting that the strength of
the association between these B-cell subsets and perhaps their effect on the pH1N1-specific B-
cell memory was best revealed by the administration of booster doses of the vaccine.
Discussion
HIV-infected children and youth developed neutralizing antibodies, had an increase in AI and
developed IgG B-cell memory after pH1N1 vaccination, demonstrating a full spectrum of
B-cell responses to the vaccine. These findings are in agreement and complement our previous
observations that HIV-infected children develop functional antibodies in response to seasonal
influenza vaccine [37]. Taken together, these observations suggest that inactivated influenza
vaccines can generally be expected to generate functional antibodies and B-cell memory in
HIV-infected children and youth with relatively conserved or reconstituted CD4 cell numbers.
B-cell memory is a critical component of the protective mechanism of vaccines, whereby the
vaccinee acquires the ability to mount a quick, anamnestic response when exposed to the path-
ogenic agent. A single administration of a double-dose of the pH1N1 vaccine was sufficient to
generate maximal IgG B-cell memory responses in the HIV-infected participants in this study.
The magnitude of the IgG and the lack of the IgA B-cell memory responses to pH1N1 were
similar to those described in HIV-infected and uninfected adults in response to split-virion
pH1N1 vaccine [38]. The magnitude of the IgG B-cell memory response in our substudy corre-
lated with the HAI and neutralizing antibody titers and with the increase in AI after
vaccination, suggesting that B-cell responses to the vaccine were coordinated in the HIV-
infected subjects.
It is important to note that the functionality, measured by neutralization and avidity, and
the memory of the antibody responses after pH1N1 immunization were higher in subjects with
HAI titers1:40 compared with those with titers<1:40 before vaccination. Older age also
played a significant role in the neutralizing antibody response to vaccination, but only in the
group with baseline titers<1:40. This suggests that presumed pre-existing exposure to pH1N1
or to seasonal H1N1 (sH1N1) with cross-reactive antibodies increased the immunogenicity of
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the vaccine. It is conceivable that previous exposure to influenza vaccines and/or infections
conferred upon older children cross-reactive B- and/or T-cell memory that improved their re-
sponses to the pH1N1 vaccine. Although there was practically no B-cell epitope homology of
the HA between the pH1N1 and the sH1N1 virus in the 2009 seasonal influenza vaccine
(which circulated in 2007 and 2008 seasons) [39], there might be B-cell epitope homology of
pH1N1 with sH1N1 circulating before 2007. Although homologies between pH1N1 and
sH1N1 before 2007 have not been extensively investigated, this hypothesis is supported by a re-
cent study that described age-associated cross-reactive antibody-dependent cellular cytotoxici-
ty against pH1N1 and sH1N1 [40]. Another potential explanation is that the extensive T-cell
epitope homology between pH1N1 and sH1N1 provided better T-cell help to the antibody re-
sponses to pH1N1 vaccine in individuals with higher sH1N1 exposure. This is in agreement
with previous studies that found increased antibody responses to pH1N1 vaccines in individu-
als/animals with prior sH1N1 vaccination/infections [41–44]. We have previously shown a
lack of association between the antibody response to pH1N1 vaccine and prior 2009 seasonal
vaccine administration [32]. We also found a lack of association between pH1N1 and sH1N1
HAI titers at baseline. However, there was a significant association of pH1N1 and sH1N1 HAI
titers after the 1st and 2nd pH1N1 immunizations (S4 Table). Other recent studies also de-
scribed boosting of heterosubtypic antibodies by vaccination or infection [45–47]. These find-
ings may be at least partially explained by cross-reactive T-cell stimulation of heterosubtypic
memory B-cell antibody production.
Other findings of our study underscore the critical role of Th cells in the immunogenicity of
the pH1N1 vaccine. pH1N1 HAI and neutralizing responses significantly correlated with
pH1N1-specific IL-2 and/or IFNγ secretion after in vitro stimulation of PBMC. It is interesting
to note that we did not find correlations of pH1N1-specific Th2-cytokine production, includ-
ing IL-4, IL-5 or IL-13, with the magnitude or functionality of antibody responses or with IgG
ASC. Other studies showed an association between IL-21 production and antibody responses
to pH1N1 vaccine in HIV-infected individuals [13,14] that we could not reproduce.
Table 5. Correlations of cellular and humoral B- and T-cell mediated immune responses to B-Cell Subsets.
Variable 1 Variable 2 Time point at which data from each variable was
analyzed
Post-dose 1 Post-dose 2
ρ (p value) N ρ (p value) N
pH1N1 HAI Titers CD19+CD10+CD27+ (immature activated) -0.09 (0.53) 51 0.28 (0.05) 48
CD19+CD10+ (immature) -0.10 (0.48) 51 0.26 (0.08) 48
Microneutralization Titers None were signiﬁcant
Antibody Avidity CD19+CD21+CD27+ (resting memory) 0.11 (0.44) 47 0.29 (0.05) 46
CD19+CD21-CD27-CD20+ (tissue-like memory) -0.23 (0.12) 47 -0.32 (0.03) 46
CD19+CD21-CD27-CD20- (transitional) -0.13 (0.40) 47 -0.33 (0.03) 46
B-cell memory (pH1N1 IgG ASC) CD19+HLADR+CD38+ (activated) -0.26 (0.16) 31 -0.36 (0.04) 33
CD19+CD10+CD27+ (immature activated) 0.06 (0.71) 40 0.40 (0.01) 37
CD19+CD21+CD27+ (resting memory) 0.28 (0.08) 40 0.50 (0.002) 37
CD19+CD21+CD27-(naïve) -0.09 (0.57) 40 -0.28 (0.09) 37
CD19+CD21-CD27-CD20+ (tissue-like memory) -0.41 (0.01) 40 -0.16 (0.35) 37
CD19+CD21-CD27-CD20- (transitional) -0.23 (0.16) 40 -0.36 (0.03) 37
CD19+CD21-CD27+CD20- (plasmablasts) 0.30 (0.06) 40 0.05 (0.77) 37
doi:10.1371/journal.pone.0118567.t005
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Furthermore, we could not detect an increase in pH1N1-specific IL-21 in culture supernatants
after vaccination, although we detected significant increases in IL-2 and IL-4.
We did not find any correlations between the markers of vaccine response and CD4% or
viral load in our analysis, likely due to the high rate of HAART utilization. This finding is
important because these HIV characteristics represent the current standard of care for HIV-
positive pediatric patients in the U.S. and in many places around the world.
We also sought to determine the relationship between the abnormal distribution of B-cell
subsets that characterizes HIV infection and pH1N1 immunogenicity. We did not observe any
changes in circulating B-cell subsets after vaccination. However, the frequency of high resting
memory B cells were associated with high pH1N1 IgG ASC and AI after vaccination, whereas
the frequency of tissue-like, transitional and/or HLADR+CD38+ activated B-cell subsets were
associated with low pH1N1 IgG ASC and antibody avidity post-vaccination. Interestingly, high
Fig 4. Correlations between pH1N1Memory B Cells (IgG ASC) and Circulating B-Cell Subsets at Baseline and after Vaccination. Data are presented
as scatter plots of pH1N1 IgG ASC/106 PBMCs on the ordinate and select B-cell subsets on the abscissa. Each row shows correlations of a single B cell
subset: CD19+CD21+CD27+ resting memory in the top row, CD19+HLADR+CD38+ activated in the middle, CD19+CD21-CD27-CD20- tissue-like on the
bottom. Columns are organized by visit: baseline on the left, post-dose 1 in the middle and post-dose 2 on the right. The correlation coefficients and p values
are shown on the graphs. The data show progression of the strengths of the correlations with each dose of vaccine.
doi:10.1371/journal.pone.0118567.g004
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frequencies of activated immature B cells were associated with increased HAI and IgG ASC re-
sponses to the vaccine. There were no associations between the frequencies of TACI+, BAFF
receptor+, or CXCR5+ B cells and responses to pH1N1 vaccine.
Our functional antibody studies showed age differences in the response to pH1N1 vaccines
that were not detected by HAI in the parent study. Although the neutralizing antibody and
HAI titers were highly correlated, only the neutralizing antibody response to the vaccine in-
creased with age. The AI also had significantly higher gains over time in older compared with
younger participants. Other studies of the functional antibody response post-pH1N1 vaccine
or infection in the general population found significant differences between elderly adults (>60
or 65 years of age) and other age groups, but no differences between younger and older chil-
dren [48,49]. There are multiple characteristics that set apart HIV-infected individuals from
the general population. Characteristics that may explain the differential effect of age on the
functional antibody responses to pH1N1 include: 1) higher attack rate of influenza infection in
HIV-infected individuals [3] and formation of B- and T-cell memory to influenza antigens; 2)
possibly higher rate of vaccination against influenza in HIV-infected children and youth due to
regular visits to health care providers; and 3) higher dependence on recall (as opposed to pri-
mary) responses to influenza vaccines in HIV-infected compared with uninfected individuals
[50].
We conclude that prior immunologic exposure to influenza vaccines and/or infections is
likely to increase the responses to heterosubtypic influenza vaccines in HIV-infected children
and youth. This effect may be mediated by cross-reactive memory B and/or Th cells. Taken to-
gether, the data suggest that repeat administration of influenza vaccine over multiple influenza
seasons or within the same season may mitigate the poor immunogenicity of these products in
HIV-infected children on HAART. Further studies with adjuvanted and live-attenuated vac-
cines are needed to identify optimal immunization regimens against influenza in
this population.
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